DiObex, Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

SAN FRANCISCO, Oct. 25 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that Keith A. Vendola, MD, Head of Corporate Development, will deliver a corporate presentation at the upcoming Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York, New York. The DiObex presentation will take place on Monday, November 5 at 4:25 p.m. at the New York Palace Hotel in the Hubbard Room.

About DiObex

DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. DiObex has two product candidates in Phase 2 clinical development. DIO-901 (very low dose glucagon) is in development as an extended release subcutaneous formulation for reducing or preventing insulin-induced hypoglycemia in type 1 diabetes mellitus. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 (levdexketoconazole) is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com.

CONTACT: Keith Vendola of DiObex, +1-415-551-4115, keith@diobex.com

Web site: http://www.diobex.com/